Budesonide in the Management of Patients with Crohn’s Disease
Modern medical therapy is increasingly based on evidence. The evidence presented here is that budesonide (Entocort, Astra Pharma) 9 mg/day is superior to placebo and equivalent to systemically active glucocorticoster...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1997-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1997/271653 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551767658725376 |
|---|---|
| author | ABR Thomson Daniel Sadowski Robert Jenkins Gary Wild |
| author_facet | ABR Thomson Daniel Sadowski Robert Jenkins Gary Wild |
| author_sort | ABR Thomson |
| collection | DOAJ |
| description | Modern medical therapy is increasingly based on evidence. The evidence presented here is that budesonide (Entocort, Astra Pharma) 9 mg/day is superior to placebo and equivalent to systemically active glucocorticosteroids in achieving disease remission in patients with active Crohn's disease, and in prolonging the recurrence time of symptomatic disease. Budesonide causes less disturbance to adrenal function than prednisone or prednisolone and may cause fewer steroid-associated symptoms. Thus, budesonide is the safer, more effective steroid of choice to treat patients with Crohn's disease. |
| format | Article |
| id | doaj-art-e213c2772536450a801ff0143e9c07b3 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1997-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-e213c2772536450a801ff0143e9c07b32025-02-03T06:00:38ZengWileyCanadian Journal of Gastroenterology0835-79001997-01-0111325526010.1155/1997/271653Budesonide in the Management of Patients with Crohn’s DiseaseABR Thomson0Daniel Sadowski1Robert Jenkins2Gary Wild3Nutrition and Metabolism Research Group, Division of Gastroenterolog, University of Alberta, Edmonton, Alberta, CanadaNutrition and Metabolism Research Group, Division of Gastroenterolog, University of Alberta, Edmonton, Alberta, CanadaAstra Pharma Inc, Mississauga, Ontario, CanadaDepartment of Anatomy and Cell Biology, Division of Gastroenterology, McGill University, Montreal, Quebec, CanadaModern medical therapy is increasingly based on evidence. The evidence presented here is that budesonide (Entocort, Astra Pharma) 9 mg/day is superior to placebo and equivalent to systemically active glucocorticosteroids in achieving disease remission in patients with active Crohn's disease, and in prolonging the recurrence time of symptomatic disease. Budesonide causes less disturbance to adrenal function than prednisone or prednisolone and may cause fewer steroid-associated symptoms. Thus, budesonide is the safer, more effective steroid of choice to treat patients with Crohn's disease.http://dx.doi.org/10.1155/1997/271653 |
| spellingShingle | ABR Thomson Daniel Sadowski Robert Jenkins Gary Wild Budesonide in the Management of Patients with Crohn’s Disease Canadian Journal of Gastroenterology |
| title | Budesonide in the Management of Patients with Crohn’s Disease |
| title_full | Budesonide in the Management of Patients with Crohn’s Disease |
| title_fullStr | Budesonide in the Management of Patients with Crohn’s Disease |
| title_full_unstemmed | Budesonide in the Management of Patients with Crohn’s Disease |
| title_short | Budesonide in the Management of Patients with Crohn’s Disease |
| title_sort | budesonide in the management of patients with crohn s disease |
| url | http://dx.doi.org/10.1155/1997/271653 |
| work_keys_str_mv | AT abrthomson budesonideinthemanagementofpatientswithcrohnsdisease AT danielsadowski budesonideinthemanagementofpatientswithcrohnsdisease AT robertjenkins budesonideinthemanagementofpatientswithcrohnsdisease AT garywild budesonideinthemanagementofpatientswithcrohnsdisease |